These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38564196)

  • 1. Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension.
    Wang X; Song F; Jiang L; Huang Z; Luo S; Li X; He X
    Am J Hypertens; 2024 Jul; 37(8):612-620. PubMed ID: 38564196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
    Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
    Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
    Supasyndh O; Sun N; Kario K; Hafeez K; Zhang J
    Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
    Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan as an Effective Hypertension Treatment Option in Those With Chronic Type B Aortic Dissection.
    Buhnerkempe MG; Bitner S; Flack JM
    Am J Hypertens; 2024 Jul; 37(8):543-545. PubMed ID: 38708518
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs.
    Han Y; Zhou Y; Na J; Li F; Sun Y
    Am J Hypertens; 2023 Nov; 36(12):643-650. PubMed ID: 37596996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.
    Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J
    J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
    Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
    Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
    Wang JG; Yukisada K; Sibulo A; Hafeez K; Jia Y; Zhang J
    J Hypertens; 2017 Apr; 35(4):877-885. PubMed ID: 28030431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive effect of sacubitril/valsartan: a meta-analysis.
    De Vecchis R; Ariano C; Soreca S
    Minerva Cardioangiol; 2019 Jun; 67(3):214-222. PubMed ID: 30895762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
    Rakugi H; Kario K; Yamaguchi M; Sasajima T; Gotou H; Zhang J
    Hypertens Res; 2022 May; 45(5):824-833. PubMed ID: 35058583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
    Ito S; Satoh M; Tamaki Y; Gotou H; Charney A; Okino N; Akahori M; Zhang J
    Hypertens Res; 2015 Apr; 38(4):269-75. PubMed ID: 25693859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis.
    Almarjan AI; Almarjan SA; Masoud AT
    High Blood Press Cardiovasc Prev; 2023 May; 30(3):207-218. PubMed ID: 37017901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
    Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials.
    Wu HX; Liu KK; Li BN; Liu S; Jin JC
    Ann Palliat Med; 2022 May; 11(5):1811-1825. PubMed ID: 35672897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
    Williams B; Cockcroft JR; Kario K; Zappe DH; Brunel PC; Wang Q; Guo W
    Hypertension; 2017 Mar; 69(3):411-420. PubMed ID: 28093466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension.
    Zhang Y; Zhao X; Huang H; Li M
    Clin Res Cardiol; 2023 Jul; 112(7):855-867. PubMed ID: 36326841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension.
    Li W; Gong M; Yu Q; Liu R; Chen K; Lv W; Yao F; Xu Z; Xu Y; Song W; Jiang Y
    J Clin Hypertens (Greenwich); 2022 Apr; 24(4):449-456. PubMed ID: 35253964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study.
    Kario K; Rakugi H; Yarimizu D; Morita Y; Eguchi S; Iekushi K
    J Am Heart Assoc; 2023 Apr; 12(8):e027612. PubMed ID: 37026551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.